France· FR:69148567
QUOFENIX 300 mg, poudre pour solution à diluer pour perfusion
A medicinal product containing délafloxacine méglumine, registered in France by MENARINI ITALIE.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DÉLAFLOXACINE MÉGLUMINE
- Manufacturer
- MENARINI ITALIE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip13340095507219510 flacon(s) en verre de 20 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Délafloxacine méglumine in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsQuofenix 300 mg, poeder voor concentraat voor oplossing voor infusieA. Menarini Industrie Farmaceutiche Riunite S.r.l.
- SwitzerlandQuofenix 300 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungA. Menarini GmbH
- SpainQUOFENIX 300 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONA. Menarini Industrie Farmaceutiche Riunite S.R.L.
- United KingdomQuofenix 300mg powder for concentrate for solution for infusion vialsA. Menarini Farmaceutica Internazionale SRL
- IcelandQuofenixA. Menarini Industrie Farmaceutiche Riunite Srl
- SwedenQuofenix 300 mg Pulver till koncentrat till infusionsvätska, lösningA Menarini Manufacturing Logistics and Services s.r.l.
- ItalyQUOFENIX*10 cpr 450 mgA.MENARINI IND.FARM.RIUN.Srl
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Quofenix
- Liechtenstein · Quofenix
- Norway · Quofenix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a8f4b228-b216-45aa-870f-a93c9d81c436 GET /v1/drugs/a8f4b228-b216-45aa-870f-a93c9d81c436?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69148567",
"date_amm": "2019-12-16",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/19/1393",
"substance": "DÉLAFLOXACINE MÉGLUMINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about délafloxacine méglumine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.